Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens.
Fetterly G, Liu B, Senzer N, Amaravadi R, Schilder R, Martin L, LoRusso P, Papadopoulos K, Adjei A, Zagst P, McKinlay M, Weng D, Graham M. Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens. Journal Of Clinical Oncology 2012, 30: 3029-3029. DOI: 10.1200/jco.2012.30.15_suppl.3029.Peer-Reviewed Original ResearchPaclitaxel/carboplatinMultiple chemotherapy regimensChemotherapy regimensWeekly dosingInterpatient variabilityLiposomal doxorubicinPK modelDose-proportional kineticsModerate interpatient variabilityPopulation PK modelPopulation PK modelingSMAC mimetic birinapantBlockade of apoptosisAdvanced malignanciesCombination regimensConcomitant administrationOral Chemotherapeutic Agents
Ogita S, LoRusso P, Li J. Oral Chemotherapeutic Agents. 2012, 1-37. DOI: 10.1002/9780470921920.edm132.Peer-Reviewed Original ResearchOral chemotherapeutic agentsInterindividual pharmacokinetic variabilityChemotherapeutic agentsPharmacokinetic variabilityImmune-modulating agentsTraditional cytotoxic agentsFirst-pass metabolismClass of agentsCytochrome P450 3A4Mechanism of actionAntiacid medicationOral agentsConcomitant administrationIntestinal effluxHormonal agentsIntravenous agentsFood effectDrug dispositionABCB1 transporterDrug resistanceClinical useCytotoxic agentsStaff time savingsP450 3A4Noninvasive administration